Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05064384 · ClinicalTrials.gov registry record

Axonics SacRal NeuromodulaTIon System RegisTRY Study

A clinical trial, sponsored by Axonics.

Completed
Registry status
272
Enrollment target

NCT05064384: Completed study, sponsored by Axonics.

NCT05064384 is a clinical trial that has completed, run by Axonics. The registered enrollment target is 272 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05064384 has completed, sponsored by Axonics.

COMPLETED
Registry status
272 participants
Enrollment target

Study Summary

To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).

Primary Outcome

Percentage of participants who were determined as responders by the treating physician when using the External Trial Stimulator and who received the Axonics System. At least a 50% reduction in symptoms is considered standard in relevant literature for response rate therefore decision for determination of responder was left to PI discretion.

Trial Details

FieldValue
Enrollment Target 272 participants
Start Date 2020-11-30
Est. Completion 2024-03-31
Axonics

7 total trials

What the finished NCT05064384 record still lists

NCT05064384 is an observational study that tracks outcomes without assigning an intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT05064384 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05064384 about?

NCT05064384 is a clinical study titled "Axonics SacRal NeuromodulaTIon System RegisTRY Study". To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).

What is the current status of trial NCT05064384?

This trial is currently completed. The enrollment target is 272 participants. The study started on 2020-11-30. Estimated completion is 2024-03-31.

Who is sponsoring clinical trial NCT05064384?

This trial is sponsored by Axonics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02468024 · 272 participants · Phase 3

    JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

  • NCT05519449 · 272 participants · Phase 1

    Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  • NCT06035939 · 272 participants · NA

    SMYLS Multi-site Trial

  • NCT06083051 · 272 participants · NA

    Differences in Postoperative Symptoms With Four Ureteral Stents

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05064384, the US trial registry maintained by the National Library of Medicine. NCT05064384 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.